Sympathetic nervous activation in obesity and the metabolic syndrome-Causes, consequences and therapeutic implications

被引:245
|
作者
Lambert, Gavin W. [1 ]
Straznicky, Nora E. [1 ,2 ,3 ]
Lambert, Elisabeth A. [1 ,2 ,3 ]
Dixon, John B. [1 ,4 ]
Schlaich, Markus P. [1 ,2 ,3 ]
机构
[1] Baker IDI Heart & Diabet Inst, Human Neurotransmitters Lab, Melbourne, Vic 8008, Australia
[2] Baker IDI Heart & Diabet Inst, Neurovasc Hypertens Lab, Melbourne, Vic 8008, Australia
[3] Baker IDI Heart & Diabet Inst, Kidney Dis Lab, Melbourne, Vic 8008, Australia
[4] Monash Univ, Obes Res Ctr, Dept Gen Practice, Clayton, Vic 3800, Australia
基金
澳大利亚国家健康与医学研究理事会;
关键词
Overweight; Metabolic syndrome; Sympathetic nervous system; Microneurography; Target organ damage; BODY-MASS-INDEX; CONVERTING ENZYME-INHIBITION; POSITIVE AIRWAY PRESSURE; LEFT-VENTRICULAR MASS; CARDIOVASCULAR RISK-FACTORS; PREDICT INSULIN-RESISTANCE; MAJOR DEPRESSIVE DISORDER; SLEEP-APNEA SYNDROME; 3RD NATIONAL-HEALTH; END-POINT REDUCTION;
D O I
10.1016/j.pharmthera.2010.02.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The world wide prevalence of obesity and the metabolic syndrome is escalating. Contrary to earlier experimental evidence, human obesity is characterised by sympathetic nervous activation, with the outflows to both the kidney and skeletal muscle being activated. While the mechanisms responsible for initiating the sympathetic activation remain to be unequivocally elucidated, hyperinsulinemia, obstructive sleep apnoea, increased circulating adipokines, stress and p adrenergic receptor polymorphisms are implicated. The pattern of sympathetic activation may be the pathophysiological mechanism underpinning much obesity-related illnesses with the consequences including, amongst others, the development of hypertension, insulin resistance, diastolic dysfunction and renal impairment. While diet and exercise are the first line therapy for the treatment of obesity and the metabolic syndrome, pharmacological interventions targeting the sympathetic nervous system, either directly or indirectly are also likely to be of benefit. Importantly, the benefit may not necessarily be weight related but may be associated with a reduction in end organ damage. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:159 / 172
页数:14
相关论文
共 50 条
  • [21] Shifting baseline syndrome: causes, consequences, and implications
    Soga, Masashi
    Gaston, Kevin J.
    FRONTIERS IN ECOLOGY AND THE ENVIRONMENT, 2018, 16 (04) : 222 - 230
  • [22] Platelet activation in obesity and metabolic syndrome
    Santilli, F.
    Vazzana, N.
    Liani, R.
    Guagnano, M. T.
    Davi, G.
    OBESITY REVIEWS, 2012, 13 (01) : 27 - 42
  • [23] Metabolic Syndrome: Definition and Therapeutic Implications
    Prasad, Hari
    Ryan, Debra A.
    Celzo, Ma Florence
    Stapleton, Dwight
    POSTGRADUATE MEDICINE, 2012, 124 (01) : 21 - 30
  • [24] Metabolic syndrome in patients with COPD: Causes and pathophysiological consequences
    Fekete, Monika
    Szollosi, Gergo
    Tarantini, Stefano
    Lehoczki, Andrea
    Nemeth, Anna N.
    Bodola, Csenge
    Varga, Luca
    Varga, Janos Tamas
    PHYSIOLOGY INTERNATIONAL, 2022, 109 (01) : 90 - 105
  • [25] Does the sympathetic nervous system contribute to the pathophysiology of metabolic syndrome?
    dos Santos Moreira, Marina C.
    de Jesus Pinto, Izabella S.
    Mourao, Aline A.
    Fajemiroye, James O.
    Colombari, Eduardo
    da Silva Reis, Angela A.
    Freiria-Oliveira, Andre H.
    Ferreira-Neto, Marcos L.
    Pedrino, Gustavo R.
    FRONTIERS IN PHYSIOLOGY, 2015, 6
  • [26] Is obstructive sleep apnea the cause of sympathetic nervous activation in human obesity?
    Esler, M
    Eikelis, N
    JOURNAL OF APPLIED PHYSIOLOGY, 2006, 100 (01) : 11 - 12
  • [27] Association between Sympathetic Nervous System Activation, Obesity and Insulin Resistance
    Kochetkov, Alexey, I
    Ostroumova, Olga D.
    Starodubova, Antonina, V
    Ostroumova, Tatyana M.
    Bondarenko, Dmitry A.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2019, 15 (02) : 230 - 243
  • [28] Oral consequences of obesity and metabolic syndrome in children and adolescents
    Salamonowicz, Malgorzata Maria
    Zalewska, Anna
    Maciejczyk, Mateusz
    DENTAL AND MEDICAL PROBLEMS, 2019, 56 (01) : 97 - 104
  • [29] Metabolic syndrome potentiates the sympathetic abnormalities characterising human obesity
    Trevano, F. Quarti
    Grassi, G.
    Seravalle, G.
    Dell'Oro, R.
    Scopelliti, F.
    Facchini, A.
    Mancia, G.
    EUROPEAN HEART JOURNAL, 2005, 26 : 241 - 241
  • [30] Role of Sympathetic Nerve Activity in Obesity, Hypertension and Metabolic Syndrome
    Masuo, Kazuko
    Esler, Murray D.
    CURRENT HYPERTENSION REVIEWS, 2010, 6 (02) : 83 - 91